Moderna mRNA 4157

$mRNA4157

First Phase 3 mRNA cancer vaccine from Moderna that crushed melanoma recurrence with Keytruda.

Specimen ID LOADING

Open PumpSwap

Live Chart

01 mRNA technology
02 Targeted immunity
03 Clinically advanced

Vial 5ml Intismeran Autogene INTerpath-001

Clinical briefing

The protocol that moved from theory to Phase 3

$mRNA4157 is the Solana memecoin named for Moderna mRNA-4157 — the individualized neoantigen therapy that just posted positive Phase 3 topline results in adjuvant melanoma.

Primary narrative @moderna_tx

Moderna and @Merck today announced positive topline results from the Phase 3 INTerpath-001 trial evaluating adjuvant treatment with intismeran autogene, a novel investigational mRNA-based individualized neoantigen therapy jointly developed by Merck and Moderna, in combination
— Moderna (@moderna_tx) August 19, 2026

Why the vial matters

Moderna and Merck reported positive topline results from INTerpath-001: adjuvant intismeran autogene plus pembrolizumab (Keytruda) in completely resected Stage IIB-IV melanoma. It is the first combination regimen to show a clinically meaningful improvement over Keytruda alone — the current standard of care.

For years the idea was science fiction: read a tumor’s genetic fingerprint, write an mRNA medicine for that patient, and train the immune system to hunt what surgery left behind. Phase 3 put a number on it. Recurrence got crushed.

This site is the Solana translation of that moment. Same name. Same symbol. Same story the world just watched land.

Compound: Intismeran autogene / mRNA-4157 / V940
Partner: Keytruda (pembrolizumab)
Study: Phase 3 INTerpath-001
Chain: Solana

mRNA technology

A writable strand. Tumor mutations in, personalized antigen cassette out. The platform that already shipped infectious-disease vaccines now writes oncology.

Targeted immunity

Not a blunt instrument. Neoantigens unique to the patient’s tumor, presented so T-cells learn the exact silhouette of what they are hunting.

Precision targeting

Adjuvant setting. After resection. The window where recurrence used to hide — now a Phase 3 readout against Keytruda alone.

Acquisition protocol

How to buy $mRNA4157

Four clinical steps. Phantom wallet, Solana, PumpSwap. No prescription required.

01

Prepare a Solana wallet

Install Phantom and create a wallet. This is your sterile field — the only instrument that signs the swap.
02

Load SOL

Bridge or buy SOL and send it to Phantom. Keep a small reserve for network fees so the dose can clear.
03

Open PumpSwap

Connect the wallet on PumpSwap. Paste the $mRNA4157 contract from the specimen strip above.
04

Swap and confirm

Select SOL to $mRNA4157, review the route, and confirm. Chart the fill on Dexscreener the moment it lands.